-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ty0lGJXVxeI3YmyScR3vm4QpyxEkfwu3B4oHhR2GgLY3Rs9wTaqM19XnVX6A1sRa
 AVDjsAk4RzccSXHKTy8x7Q==

<SEC-DOCUMENT>0001019687-07-002672.txt : 20070817
<SEC-HEADER>0001019687-07-002672.hdr.sgml : 20070817
<ACCEPTANCE-DATETIME>20070817164147
ACCESSION NUMBER:		0001019687-07-002672
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070817
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070817
DATE AS OF CHANGE:		20070817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		071065616

	BUSINESS ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		2129120930

	MAIL ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-081607.txt
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 17, 2007

                              AETHLON MEDICAL, INC.
               (Exact name of Registrant as specified in charter)


Nevada                               000-21846            13-3632859
- ------                               ---------            ----------
(State or other jurisdiction  (Commission File Number)    (IRS Employer
of incorporation)                                         Identification Number)

                       3030 Bunker Hill Street, Suite 4000
                           San Diego, California 92109
                    (Address of principal executive offices)


       Registrant's telephone number, including area code: (858) 459-7800

                                 NOT APPLICABLE
          (Former name or former address, if changed since last report)


<PAGE>

FORWARD LOOKING STATEMENTS

         This Form 8-K and other reports filed by Registrant from time to time
with the Securities and Exchange Commission (collectively the "Filings") contain
or may contain forward looking statements and information that are based upon
beliefs of, and information currently available to, Registrant's management as
well as estimates and assumptions made by Registrant's management. When used in
the Filings the words "anticipate, "believe", "estimate", "expect", "future",
"intend", "plan" or the negative of these terms and similar expressions as they
relate to Registrant or Registrant's management identify forward looking
statements. Such statements reflect the current view of Registrant with respect
to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results
of operations and any businesses that may be acquired by Registrant. Should one
or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.

         Although Registrant believes that the expectations reflected in the
forward looking statements are reasonable, Registrant cannot guarantee future
results, levels of activity, performance or achievements. Except as required by
applicable law, including the securities laws of the United States, Registrant
does not intend to update any of the forward-looking statements to conform these
statements to actual results.


ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

         On August 13, 2007, the Registrant issued and sold Common Stock, $0.001
par value, and warrants to purchase Common Stock, in the form of units (the
"Unit"). Each Unit is comprised of (i) two shares of Common Stock of the
Registrant, and (ii) one warrant to purchase one share of Common Stock at an
exercise price of $0.50 per share (the "Warrants"). The Warrants expire three
years after the date of issuance of the Warrant. Each Unit was sold for $1.00,
and the aggregate gross proceeds to the Registrant were $815,000, for the
issuance and sale of 815,000 Units. The Units were issued to accredited
investors only, and the Registrant relied on the exemption from registration
under Regulation D, Section 506 of the Securities Act of 1933, as amended (the
"Act"). In connection with the offering a fee equal to 7% of the gross proceeds
was paid to a broker and to a finder. The fee was paid in a combination of cash
and Common Stock. The offering closed on August 14, 2007 (the "Closing Date").

         In connection with the issuance and sale of the Units, the Registrant
granted registration rights to the holders of the Units, as follows: the
Registrant will use its best efforts to register the Common Stock and Common
Stock underlying the warrants under the Act within sixty (60) days from the
Closing Date. The Registrant shall use its best efforts to cause the
registration statement to be declared effective within one hundred eighty (180)
calendar days from the Closing Date. If not effective by that time, then the
Registrant shall pay to the investors additional shares of Common Stock equal to
two percent (2%) per month (or any part thereof ) of the number of shares of
Common Stock sold pursuant to the Unit offering, payable within thirty (30)
business days of the end of each month beyond the required effective date. No
penalty shares shall be issued if the investors are able to rely on Rule 144
under the Act to sell their Common Stock.


                                       2

<PAGE>

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

EXHIBITS

Item No.     Description
- --------     -----------

4.1          Form of Common Stock Purchase Warrant

10.1         Form of Subscription Agreement




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:   August 17, 2007

                                              AETHLON MEDICAL, INC.

                                              By: /s/ James A. Joyce
                                                  ------------------------------
                                              James A. Joyce
                                              Chief Executive Officer





                                       3



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>aethlon_8kex4-1.txt
<DESCRIPTION>FORM OF COMMON STOCK PURCHASE WARRANT
<TEXT>
<PAGE>

                                                                     EXHIBIT 4.1


THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT
AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO AETHLON MEDICAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

                                Right to  Purchase  ___,___  of shares of Common
                                Stock of Aethlon Medical, Inc. (subject to
                                adjustment as provided herein)


                          COMMON STOCK PURCHASE WARRANT

No. 0813-______                                      Issue Date: August 13, 2007

         AETHLON MEDICAL, INC., a corporation organized under the laws of the
State of Nevada (the "Company"), hereby certifies that, for value received,
____________________. or its assigns (the "Holder"), is entitled, subject to the
terms set forth below, to purchase from the Company at any time after the Issue
Date until 5:00 p.m., P.S.T. on the third anniversary of the Issue Date (the
"Expiration Date"), up to _________________________ (XXX,000) fully paid and
nonassessable shares of the common stock of the Company (the "Common Stock"), at
a per share purchase price of $0.50. The aforedescribed purchase price per
share, as adjusted from time to time as herein provided, is referred to herein
as the "Purchase Price." The number and character of such shares of Common Stock
and the Purchase Price are subject to adjustment as provided herein. The Company
may reduce the Purchase Price without the consent of the Holder.

         As used herein the following terms, unless the context otherwise
requires, have the following respective meanings:

         (a) The term "Company" shall include Aethlon Medical, Inc. and any
corporation which shall succeed or assume the obligations of Aethlon Medical,
Inc. hereunder.

         (b) The term "Common Stock" includes (a) the Company's Common Stock and
(b) any other securities into which or for which any of the securities described
in (a) may be converted or exchanged pursuant to a plan of recapitalization,
reorganization, merger, sale of assets or otherwise.

          (c) The term "Other Securities" refers to any stock (other than Common
Stock) and other securities of the Company or any other person (corporate or
otherwise) which the holder of the Warrant at any time shall be entitled to
receive, or shall have received, on the exercise of the Warrant, in lieu of or
in addition to Common Stock, or which at any time shall be issuable or shall
have been issued in exchange for or in replacement of Common Stock or Other
Securities pursuant to Section 4 or otherwise.

         1. EXERCISE OF WARRANT.

                  1.1. NUMBER OF SHARES ISSUABLE UPON EXERCISE. From and after
the Issue Date through and including the Expiration Date, the Holder hereof
shall be entitled to receive, upon exercise of this Warrant in whole in
accordance with the terms of subsection 1.2 or upon exercise of this Warrant in
part in accordance with subsection 1.3, shares of Common Stock of the Company,
subject to adjustment pursuant to Section 4.


                                       1

<PAGE>

                  1.2. FULL EXERCISE. This Warrant may be exercised in full by
the Holder hereof by delivery of an original or facsimile copy of the form of
subscription attached as Exhibit A hereto (the "Subscription Form") duly
executed by such Holder and surrender of the original Warrant within seven (7)
days of exercise, to the Company at its principal office or at the office of its
Warrant Agent (as provided hereinafter), accompanied by payment, in cash, wire
transfer or by certified or official bank check payable to the order of the
Company, in the amount obtained by multiplying the number of shares of Common
Stock for which this Warrant is then exercisable by the Purchase Price then in
effect or by cashless exercise in the manner set forth in Section 2.

                  1.3. PARTIAL EXERCISE. This Warrant may be exercised in part
(but not for a fractional share) by surrender of this Warrant in the manner and
at the place provided in subsection 1.2 except that the amount payable by the
Holder on such partial exercise shall be the amount obtained by multiplying (a)
the number of whole shares of Common Stock designated by the Holder in the
Subscription Form by (b) the Purchase Price then in effect. On any such partial
exercise, the Company, at its expense, will forthwith issue and deliver to or
upon the order of the Holder hereof a new Warrant of like tenor, in the name of
the Holder hereof or as such Holder (upon payment by such Holder of any
applicable transfer taxes) may request, the whole number of shares of Common
Stock for which such Warrant may still be exercised.

                  1.4. COMPANY ACKNOWLEDGMENT. The Company will, at the time of
the exercise of the Warrant, upon the request of the Holder hereof acknowledge
in writing its continuing obligation to afford to such Holder any rights to
which such Holder shall continue to be entitled after such exercise in
accordance with the provisions of this Warrant. If the Holder shall fail to make
any such request, such failure shall not affect the continuing obligation of the
Company to afford to such Holder any such rights.

                  1.5. TRUSTEE FOR WARRANT HOLDERS. In the event that a bank or
trust company shall have been appointed as trustee for the Holder of the
Warrants pursuant to Subsection 3.2, such bank or trust company shall have all
the powers and duties of a warrant agent (as hereinafter described) and shall
accept, in its own name for the account of the Company or such successor person
as may be entitled thereto, all amounts otherwise payable to the Company or such
successor, as the case may be, on exercise of this Warrant pursuant to this
Section 1.

                  1.6 DELIVERY OF STOCK CERTIFICATES, ETC. ON EXERCISE. The
Company agrees that the shares of Common Stock purchased upon exercise of this
Warrant shall be deemed to be issued to the Holder hereof as the record owner of
such shares as of the close of business on the date on which this Warrant shall
have been surrendered and payment made for such shares as aforesaid. As soon as
practicable after the exercise of this Warrant in full or in part, and in any
event within five (5) days thereafter, the Company at its expense (including the
payment by it of any applicable issue taxes) will cause to be issued in the name
of and delivered to the Holder hereof, or as such Holder (upon payment by such
Holder of any applicable transfer taxes) may direct in compliance with
applicable securities laws, a certificate or certificates for the number of duly
and validly issued, fully paid and nonassessable shares of Common Stock (or
Other Securities) to which such Holder shall be entitled on such exercise, plus,
in lieu of any fractional share to which such Holder would otherwise be
entitled, cash equal to such fraction.

         2. REGISTRATION RIGHTS. The Company shall file a registration statement
on Form SB-2 or other appropriate registration form under the Securities Act
(the "Registration Statement") for the registration of the shares of Common
Stock underlying this Warrant (the "Warrant Shares") and shall use its
reasonable best efforts to maintain the Registration Statement effective so long
as this Warrant is outstanding (the "Effectiveness Period"). The Company shall
file such Registration Statement no later than sixty (60) days after August 13,
2007; provided, however, the Company will not be obligated to register more than
33% of its issued and outstanding shares of Common Stock on such registration


                                       2

<PAGE>

statement. If the number of shares of Common Stock and the Warrant Shares
proposed to be registered thereunder exceeds such 33% limitation, the Company
will cut back the number of shares being registered in order for it to adhere to
such 33% limitation, and such cut back will be applied to the holders of the
shares being registered (including the Holder hereof) on a pro rata basis. The
Company shall also use its best efforts to ensure that such Registration
Statement is declared effective within one hundred and eighty (180) calendar
days from August 13, 2007. Except as otherwise expressly set forth, the Company
shall bear all expenses incurred by the Company in compliance with this
registration obligation of the Company, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of
counsel for the Company incurred in connection with any registration,
qualification or compliance concerning the Warrant Shares.

         3. ADJUSTMENT FOR REORGANIZATION, CONSOLIDATION, MERGER, ETC.

                  3.1. REORGANIZATION, CONSOLIDATION, MERGER, ETC. In case at
any time or from time to time, the Company shall (a) effect a reorganization,
(b) consolidate with or merge into any other person or (c) transfer all or
substantially all of its properties or assets to any other person under any plan
or arrangement contemplating the dissolution of the Company, then, in each such
case, as a condition to the consummation of such a transaction, proper and
adequate provision shall be made by the Company whereby the Holder of this
Warrant, on the exercise hereof as provided in Section 1, at any time after the
consummation of such reorganization, consolidation or merger or the effective
date of such dissolution, as the case may be, shall receive, in lieu of the
Common Stock (or Other Securities) issuable on such exercise prior to such
consummation or such effective date, the stock and other securities and property
(including cash) to which such Holder would have been entitled upon such
consummation or in connection with such dissolution, as the case may be, if such
Holder had so exercised this Warrant, immediately prior thereto, all subject to
further adjustment thereafter as provided in Section 4.

                  3.2. DISSOLUTION. In the event of any dissolution of the
Company following the transfer of all or substantially all of its properties or
assets, the Company, prior to such dissolution, shall at its expense deliver or
cause to be delivered the stock and other securities and property (including
cash, where applicable) receivable by the Holder of the Warrants after the
effective date of such dissolution pursuant to this Section 3 to a bank or trust
company (a "Trustee") having its principal office in Los Angeles, California, as
trustee for the Holder of the Warrants.

                  3.3. CONTINUATION OF TERMS. Upon any reorganization,
consolidation, merger or transfer (and any dissolution following any transfer)
referred to in this Section 3, this Warrant shall continue in full force and
effect and the terms hereof shall be applicable to the Other Securities and
property receivable on the exercise of this Warrant after the consummation of
such reorganization, consolidation or merger or the effective date of
dissolution following any such transfer, as the case may be, and shall be
binding upon the issuer of any Other Securities, including, in the case of any
such transfer, the person acquiring all or substantially all of the properties
or assets of the Company, whether or not such person shall have expressly
assumed the terms of this Warrant as provided in Section 4. In the event this
Warrant does not continue in full force and effect after the consummation of the
transaction described in this Section 3, then only in such event will the
Company's securities and property (including cash, where applicable) receivable
by the Holder of the Warrants be delivered to the Trustee as contemplated by
Section 3.2.

         4. EXTRAORDINARY EVENTS REGARDING COMMON STOCK. In the event that the
Company shall (a) issue additional shares of the Common Stock as a dividend or
other distribution on outstanding Common Stock, (b) subdivide its outstanding
shares of Common Stock, or (c) combine its outstanding shares of the Common
Stock into a smaller number of shares of the Common Stock, then, in each such
event, the Purchase Price shall, simultaneously with the happening of such
event, be adjusted by multiplying the then Purchase Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such event and the denominator of which shall be the number
of shares of Common Stock outstanding immediately after such event, and the
product so obtained shall thereafter be the Purchase Price then in effect. The
Purchase Price, as so adjusted, shall be readjusted in the same manner upon the
happening of any successive event or events described herein in this Section 4.


                                       3

<PAGE>

The number of shares of Common Stock that the Holder of this Warrant shall
thereafter, on the exercise hereof as provided in Section 1, be entitled to
receive shall be adjusted to a number determined by multiplying the number of
shares of Common Stock that would otherwise (but for the provisions of this
Section 4) be issuable on such exercise by a fraction of which (a) the numerator
is the Purchase Price that would otherwise (but for the provisions of this
Section 4) be in effect, and (b) the denominator is the Purchase Price in effect
on the date of such exercise.

         5. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of the Warrants, the Company at its expense will promptly cause its
Chief Financial Officer or other appropriate designee to compute such adjustment
or readjustment in accordance with the terms of the Warrant and prepare a
certificate setting forth such adjustment or readjustment and showing in detail
the facts upon which such adjustment or readjustment is based, including a
statement of (a) the consideration received or receivable by the Company for any
additional shares of Common Stock (or Other Securities) issued or sold or deemed
to have been issued or sold, (b) the number of shares of Common Stock (or Other
Securities) outstanding or deemed to be outstanding, and (c) the Purchase Price
and the number of shares of Common Stock to be received upon exercise of this
Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith
mail a copy of each such certificate to the Holder of the Warrant and any
Warrant Agent of the Company (appointed pursuant to Section 11 hereof).

         6. RESERVATION OF STOCK, ETC. ISSUABLE ON EXERCISE OF WARRANT;
FINANCIAL STATEMENTS. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of the Warrants, all shares of
Common Stock (or Other Securities) from time to time issuable on the exercise of
the Warrant. This Warrant entitles the Holder hereof to receive copies of all
financial and other information distributed or required to be distributed to the
holders of the Company's Common Stock.

         7. ASSIGNMENT; EXCHANGE OF WARRANT. Subject to compliance with
applicable securities laws, this Warrant, and the rights evidenced hereby, may
be transferred by any registered holder hereof (a "Transferor"). On the
surrender for exchange of this Warrant, with the Transferor's endorsement in the
form of Exhibit B attached hereto (the "Transferor Endorsement Form") and
together with an opinion of counsel reasonably satisfactory to the Company that
the transfer of this Warrant will be in compliance with applicable securities
laws, the Company at its expense, but with payment by the Transferor of any
applicable transfer taxes, will issue and deliver to or on the order of the
Transferor thereof a new Warrant or Warrants of like tenor, in the name of the
Transferor and/or the transferee(s) specified in such Transferor Endorsement
Form (each a "Transferee"), calling in the aggregate on the face or faces
thereof for the number of shares of Common Stock called for on the face or faces
of the Warrant so surrendered by the Transferor. No such transfers shall result
in a public distribution of the Warrant.

         8. REPLACEMENT OF WARRANT. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction of this
Warrant, on delivery of an indemnity agreement or security reasonably
satisfactory in form and amount to the Company or, in the case of any such
mutilation, on surrender and cancellation of this Warrant, the Company at its
expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of
like tenor.


                                       4

<PAGE>

         9. WARRANT AGENT. The Company may, by written notice to the Holder of
the Warrant, appoint an agent (a "Warrant Agent") for the purpose of issuing
Common Stock (or Other Securities) on the exercise of this Warrant pursuant to
Section 1, exchanging this Warrant pursuant to Section 7, and replacing this
Warrant pursuant to Section 8, or any of the foregoing, and thereafter any such
issuance, exchange or replacement, as the case may be, shall be made at such
office by such Warrant Agent.

         10. TRANSFER ON THE COMPANY'S BOOKS. Until this Warrant is transferred
on the books of the Company, the Company may treat the registered holder hereof
as the absolute owner hereof for all purposes, notwithstanding any notice to the
contrary.

         11. NOTICES. All notices, demands, requests, consents, approvals, and
other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii)
deposited in the mail, registered or certified, return receipt requested,
postage prepaid, (iii) delivered by reputable air courier service with charges
prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Company to: Aethlon Medical, Inc.,
3030 Bunker Hill Street, Suite 4000, San Diego, California 92109, FAX: (858)
332-1739, with a copy by facsimile only to: Richardson & Patel LLP, 10900
Wilshire Boulevard, Suite 500, Los Angeles, CA 90024, Attn: Nimish Patel, Esq.,
telecopier: (310) 208-1154, (ii) if to the Holder, to the address and facsimile
number listed on the first paragraph of this Warrant.

         12. MISCELLANEOUS. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination
is sought. This Warrant shall be construed and enforced in accordance with and
governed by the laws of California. Any dispute relating to this Warrant shall
be adjudicated in City of Los Angeles in the State of California. The headings
in this Warrant are for purposes of reference only, and shall not limit or
otherwise affect any of the terms hereof. The invalidity or unenforceability of
any provision hereof shall in no way affect the validity or enforceability of
any other provision.

         IN WITNESS WHEREOF, the Company has executed this Warrant as of the
date first written above.

                              AETHLON MEDICAL, INC.



                                    By: /s/ James A. Joyce
                                        ----------------------------------------
                                    Name: James A. Joyce
                                    Title:  Chairman and Chief Executive Officer



  Witness:

- ----------------------------


                                       5


<PAGE>



                                    Exhibit A

                               FORM OF SUBSCRIPTION
                       (to be signed only on exercise of Warrant)


TO:  AETHLON MEDICAL, INC.

The undersigned, pursuant to the provisions set forth in the attached Warrant
(No.____), hereby irrevocably elects to purchase:

____________ shares of the Common Stock covered by such Warrant.

The undersigned herewith makes payment of the full purchase price for such
shares at the price per share provided for in such Warrant, which is
$_______________. Such payment takes the form of:

 $_________________ in lawful money of the United States

The undersigned requests that the certificates for such shares be issued in the
name of, and delivered to _________________________________________ whose
address is

________________________________________________________________________________

________________________________________________________________________________

The undersigned represents and warrants that all offers and sales by the
undersigned of the securities issuable upon exercise of the within Warrant shall
be made pursuant to registration of the Common Stock under the Securities Act of
1933, as amended (the "Securities Act"), or pursuant to an exemption from
registration under the Securities Act.


Dated: _______________________


Signature:_________________________________
          (Signature must conform to name of holder as
           specified on the face of the Warrant)

Address: __________________________________

         __________________________________

         __________________________________


                                       6
<PAGE>

                                  Exhibit B


                         FORM OF TRANSFEROR ENDORSEMENT
                   (To be signed only on transfer of Warrant)


For value received, the undersigned hereby sells, assigns, and transfers unto
the person(s) named below under the heading "Transferees" the right represented
by the within Warrant to purchase the percentage and number of shares of Common
Stock of AETHLON MEDICAL, INC. to which the within Warrant relates specified
under the headings "Percentage Transferred" and "Number Transferred,"
respectively, opposite the name(s) of such person(s) and appoints each such
person Attorney to transfer its respective right on the books of AETHLON
MEDICAL, INC. with full power of substitution in the premises.

- --------------------------------------------------------------------------------
Transferees                Percentage Transferred             Number Transferred
- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------




Dated: ____________________,__________

Signature: _______________________________________________________
           (Signature must conform to name of holder as specified
            on the face of the warrant)

Signed in the presence of:

_______________________________        _____________________________________
        (Name)
                                       _____________________________________
                                            (address)

ACCEPTED AND AGREED:                   _____________________________________
[TRANSFEREE]
                                       _____________________________________
                                            (address)


_______________________________
        (Name)


                                       7
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>aethlon_8kex10-1.txt
<DESCRIPTION>FORM OF SUBSCRIPTION AGMT.
<TEXT>
<PAGE>

                                                                EXHIBIT 10.1

                             SUBSCRIPTION AGREEMENT

         The undersigned (hereinafter "SUBSCRIBER") hereby confirms its
subscription for the purchase of Units comprised of shares of Common Stock, par
value $.001 per share ("Common Stock"), of AETHLON MEDICAL, INC., a Nevada
corporation (the "COMPANY"), and warrants exercisable for Common Stock
("Warrants"), on the terms described below.

         The Units, the Common Stock, the Warrants and the shares issuable upon
exercise of the Warrants ("Warrant Shares") are sometimes referred to
collectively herein as the "SECURITIES."

         In connection with this subscription, Subscriber and the Company agree
as follows:

A. SUBSCRIPTION OF THE SUBSCRIBER.

         1. PURCHASE OF UNITS. The undersigned (the "Subscriber") hereby
irrevocably agrees, represents and warrants with, to and for the benefit of the
Company, that such Subscriber is executing this Agreement in connection with the
subscription by the Subscriber for _______ units of the Company ("Units"), with
each Unit consisting of (i) two shares of Common Stock of the Company and (ii)
one Warrant to purchase one share of Common Stock of the Company for an exercise
price of $0.50 per share, at a price per Unit of $1.00, resulting in the
aggregate purchase price set forth on the Subscriber's signature page hereto
(the "Offering Price"). The Common Stock and the Warrants (and the Warrant
Shares) are sometimes referred to hereinafter collectively as the "Underlying
Stock". The Subscriber understands that the Company is relying upon the accuracy
and completeness of the information contained herein in complying with its
obligations under federal and state securities and other applicable laws.
Subject to the terms and conditions of this Agreement, upon execution and
delivery hereof by the Subscriber, the Subscriber hereby agrees to purchase the
Units of the Company pursuant to the transaction hereof, and against concurrent
delivery of the purchase price for such Units. The date upon which the final
subscription is accepted by the Company and the full Offering Price has been
tendered to the Company, shall be known as the "Closing Date."

         2. OFFERING. This offering of the Units (the "Offering") is being made
to a limited group of investors, all of whom shall represent to the Company
pursuant to this Agreement that they are "accredited investors," as that term is
defined in Regulation D promulgated under the Securities Act of 1933, as amended
(the "Securities Act") or who have otherwise been qualified as investors by the
Company. All of the Units offered hereby are being sold by the Company. The
Company is offering Units for the consideration set forth herein. The Company
may sell less than all of the Units, and shall be entitled to accept
subscriptions and receive the Offering Price for each subscription prior to the
entire Offering being subscribed for. The Offering is being made on a "best
efforts" basis. The minimum subscription amount is $25,000.

B. REPRESENTATIONS AND WARRANTIES OF THE SUBSCRIBER. The Subscriber hereby
represents and warrants to the Company as of the date hereof:

                                       1

<PAGE>

         1. PLACE OF BUSINESS. The principal place of business address set forth
below is such Subscriber's true and correct principal place of business and is
the only jurisdiction in which an offer to sell the Units was made to such
Subscriber and such Subscriber has no present intention of moving its principal
place of business to or of becoming a resident of any other state or
jurisdiction.

         2. SALE OR TRANSFER OF THE UNITS AND UNDERLYING STOCK. The Subscriber
understands that neither the Units nor any of the Underlying Stock has been
registered under the Securities Act, or under the laws of any other
jurisdiction. The Subscriber understands and agrees that transfer or sale of the
Units and the Underlying Stock may be restricted or prohibited unless they are
subsequently registered under the Securities Act and, where required, under the
laws of other jurisdictions or an exemption from registration is available. The
Subscriber will not offer, sell, transfer or assign its Units or Underlying
Stock or any interest therein in contravention of this Agreement, the Securities
Act or any state or federal law. The Subscriber understands and acknowledges
that, because of the substantial restrictions on the transferability of the
Units and Underlying Stock, it may not be possible for the Subscriber to
liquidate the Subscriber's investment in the Company readily, even in the case
of an emergency.

         3. REPRESENTATION OF ACCREDITED INVESTOR STATUS, INVESTMENT EXPERIENCE
AND ABILITY TO BEAR RISK. Subscriber acknowledges that the Offering has not been
registered with the Securities and Exchange Commission because the Company is
relying on an exemption from registration under Section 4(2) of the Securities
Act and Regulation D promulgated thereunder. SUBSCRIBER BELIEVES THAT AT THE
TIME OF THE SALE OF THE UNITS TO SUBSCRIBER, SUBSCRIBER (OR, IF SUBSCRIBER IS A
CORPORATION, LIMITED LIABILITY COMPANY OR TRUST, EACH OF ITS EQUITY OWNERS)
QUALIFIES AS AN "ACCREDITED INVESTOR" (AS DEFINED UNDER RULE 501 OF REGULATION D
PROMULGATED UNDER THE SECURITIES ACT) USING THE FOLLOWING QUALIFICATION FACTORS
(CHECK ALL APPROPRIATE ITEMS):

 (__)     $1,000,000 NET WORTH TEST:

          I, Subscriber, am a natural person and my individual net worth, or
          joint net worth with my spouse (if any), INCLUSIVE of home,
          furnishings and automobiles, at the time of this purchase is in excess
          of $1,000,000.

  (__)    $200,000 INDIVIDUAL/$300,000 JOINT ANNUAL INCOME TEST:

          I, Subscriber, am a natural person and my individual annual gross
          income (exclusive of my spouse's income) has been in excess of
          $200,000 in each of the two most recent tax years, and I reasonably
          expect individual annual gross income (exclusive of my spouse's
          income) to be in excess of $200,000 for the current tax year; or I am
          a natural person and my joint annual gross income (including my
          spouse's annual gross income) has been in excess of $300,000 in each
          of the two most recent tax years, and I reasonably expect our joint
          annual gross incomes to be in excess of $300,000 for the current tax
          year.

                                       2

<PAGE>

          ("INCOME" under this test is defined as adjusted gross income for
          federal income tax purposes PLUS (i) deductions for long-term capital
          gains under the Internal Revenue Code; (ii) deductions for depletion
          under section 611 et seq. of the Code; (iii) any exclusion for
          interest received on tax-exempt securities; and (iv) any losses of a
          Company allocated to the individual limited partners of the Company as
          reported on Form 1040).

 (__)     BANK OR INVESTMENT COMPANY TEST:

          Subscriber is a bank as defined in section 3(a)(2) of the
          Securities Act, or any savings and loan association or other
          institution as defined in section 3(a)(5)(A) of the Securities Act,
          whether acting in its individual or fiduciary capacity; or is a broker
          or dealer registered pursuant to section 15 of the Securities Exchange
          Act of 1934; or is an insurance company as defined in section 2(13) of
          the Securities Act; or is any investment company registered under the
          Investment Corporation Act of 1940, or a business development company
          as defined in section 2(a)(48) of that Act; or is a Small Business
          Investment Corporation licensed by the U.S. Small Business
          Administration under section 301(c) or (d) of the Small Business
          Investment Act of 1958; is a plan established and maintained by a
          state, its political subdivision, or any agency or instrumentality of
          a state or its political subdivisions, for the benefit of its
          employees, if such plan has total assets in excess of $5,000,000; or
          is an employee benefit plan within the meaning of the employee
          Retirement Income Security Act of 1974, if the investment decision is
          made by a plan fiduciary, as defined in section 3(21) of such Act,
          which is either a bank, savings and loan association, insurance
          company, or registered investment adviser, or if the employee benefit
          plan has total assets in excess of $5,000,000, or, if a self-directed
          plan, with investment decisions made solely by persons that are
          accredited investors.

  (__)    PRIVATE BUSINESS DEVELOPMENT CORPORATION TEST:

          Subscriber is a private business development company as defined in
          section 202(a)(22) of the Investment Advisors Act of 1940.

 (__)     IRC SECTION 501(c)(3) ORGANIZATION TEST:

          Subscriber is an organization described in Section 501(c)(3) of the
          Internal Revenue Code, corporation, Massachusetts or similar business
          trust, or Company, not formed for the specific purpose of acquiring
          the securities being offered, with total assets in excess of
          $5,000,000.

 (__)     DIRECT RELATIONSHIP TO ISSUER TEST:

          Subscriber is a director, executive officer, partner or manager of
          the Company of the securities being offered or sold, or any director,
          executive officer or manager of a partner or partner of that issuer.

                                       3

<PAGE>

(__)      $5,000,000 NONINVESTMENT TRUST TEST:

          Subscriber is a trust with total assets in excess of $5,000,000 not
          formed for the specific purpose of acquiring the securities being
          offered, whose purchase is directed by a "sophisticated person" as
          described in section 230.506(b)(2)(ii).

 (__)     EQUITY ENTITY COMPRISED OF ACCREDITED INVESTORS TEST:

          Subscriber is any equity entity in which all of the equity owners
          are accredited investors as defined above. Subscriber has had one of
          the persons responsible for overseeing and/or managing one or more of
          Subscriber's financial accounts complete the attestation in Section D
          hereof in order to verify the information in this Section B:

          Yes _________           No _________


In addition, Subscriber is knowledgeable and experienced with respect to the
financial and business activities contemplated by the Company and is capable of
evaluating the risks and merits of investing in the Units and, in making a
decision to proceed with this investment, has not relied upon any
representations, warranties or agreements, other than those set forth in this
Agreement and can bear the economic risk of an investment in the Company for an
indefinite period of time, and can afford to suffer the complete loss thereof.

         4. OWN ADVICE. In connection with the Subscriber's investment in the
Company, the Subscriber has carefully considered and has, to the extent the
Subscriber believes such discussion necessary, discussed with the Subscriber's
professional legal, tax and financial advisers (the "Investment Advisors") the
suitability of an investment in the Units for the Subscriber's particular tax
and financial situation and the Subscriber has determined that the Units are a
suitable investment for the Subscriber.

         5. COMPANY HISTORY; RISKS. The Subscriber represents and warrants that
the Subscriber is aware (i) that the Company has limited operating history; (ii)
that the Units involve a substantial degree of risk of loss of the Subscriber's
entire investment and that there is no assurance of any income from the
Subscriber's investment; and (iii) that any federal and/or state income tax
benefits which may be available to the Subscriber, if any, may be lost through
the adoption of new laws or regulations, to changes to existing laws and
regulations and to changes in the interpretation of existing laws and
regulations. The Subscriber further represents that the Subscriber is relying
solely on the Subscriber's own conclusions or the advice of the Subscriber's
Investment Advisors with respect to tax aspects of any investment in the Units.

                                       4

<PAGE>

         6. INQUIRIES. The Subscriber and its Investment Advisors have been
given access to, and prior to the execution of this Agreement, have been
provided with an opportunity to ask questions of, and receive answers from, the
Company officers concerning the Company and the terms and conditions of the
Offering and the Units, and to obtain any other information which the Subscriber
and the Subscriber's Investment Advisors required with respect to the Company
and an investment in the Company in order to evaluate such investment and verify
the accuracy of all information furnished to the Subscriber and its Investment
Advisors regarding the Company. All such questions, if asked, were answered
satisfactorily and all information or documents provided were found to be
satisfactory. Neither the Subscriber nor its Investment Advisors have been
furnished any offering literature on which they have relied on other this
Agreement and the Subscriber and its Investment Advisors have relied only on
this Agreement. At no time was the Subscriber presented with or solicited by any
leaflet, public promotion meeting, newspaper or magazine article, radio or
television advertisement or any other form of general advertising or general
solicitation.

         7. AUTHORITY. The Subscriber is authorized and has full right and power
to subscribe for the Units and to perform the Subscriber's obligations pursuant
to the provisions of this Agreement; the person signing this Agreement and any
other instrument executed and delivered herewith on behalf of such Subscriber
has been duly authorized by such entity and has full power and authority to do
so. If the Subscriber is a corporation, partnership, unincorporated association
or other entity, the person signing this agreement has the legal capacity to
authorize, deliver and be bound by this Subscription Agreement and to take all
actions required pursuant hereto and further certifies that all necessary
approvals of directors, shareholders or otherwise have been given and obtained;
and if the Subscriber is an individual, it is of the full age of majority in the
jurisdiction in which the Subscriber is resident and is legally competent to
execute, deliver and be bound by this Subscription Agreement and take all action
pursuant hereto.

         8. NO DEFAULT. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby and thereby will not
conflict with, or result in any violation of or default pursuant to, any
provision of any governing instrument applicable to the Subscriber, or any
agreement or other instrument to which the Subscriber is a party or by which the
Subscriber or any of the Subscriber's properties are bound or any permit,
franchise, judgment, decree, statute, rule or regulation applicable to the
Subscriber or any of the Subscriber's business or properties.

         9. ERISA. If the Subscriber is an employee benefit plan subject to
ERISA, then such Subscriber acknowledges that such Subscriber has been informed
of and understands the operations and business of the Company, and represents
that such Subscriber's investment in the Company (i) is permissible under the
documents and instruments governing such plan; (ii) satisfies the
diversification requirements of ERISA; (iii) is prudent considering all the
facts and circumstances, including the fact that there is no trading market for
the Units or the Underlying Stock; and (iv) is not a "prohibited transaction"
within the meaning of Section 406 of ERISA.

                                       5

<PAGE>

         10. PURCHASE ENTIRELY FOR OWN ACCOUNT. This Agreement is made with the
Subscriber in reliance upon the Subscriber's representations to the Company,
which by the Subscriber's execution of this Agreement, the Subscriber hereby
confirms, that the Units issuable to the Subscriber will be acquired for
investment for the Subscriber's own account, not as a nominee or agent, and not
with a view to the resale or distribution of any part thereof, and that the
Subscriber has no present intention of selling, granting any participation in,
or otherwise distributing the same. The Subscriber represents and warrants that
the Subscriber has no contract, understanding, agreement or arrangement with any
person to sell or transfer or pledge to such person or anyone else any of the
Units for which the Subscriber hereby subscribes (in whole or in part) or any
interest therein; and the Subscriber represents and warrants that the Subscriber
has no present plans to enter into any such contract, undertaking, agreement or
arrangement.

         The Subscriber represents and warrants that the funds representing the
Aggregate Subscription Price which will be advanced by the Subscriber hereunder
will not represent proceeds of crime and the Subscriber acknowledges that the
Company or the Placement Agents may in the future be required by law to disclose
the Subscriber's name and other information relating to this Subscription
Agreement and the Subscriber's subscription hereunder, on a confidential basis,
and to the best of the Subscriber's knowledge (i) none of the subscription funds
to be provided by the Subscriber (a) have been or will be derived from or
related to any activity that is deemed criminal under the laws of the United
States of America, or any other jurisdiction, or (b) are being tendered on
behalf of a person or entity who has not been identified to the Subscriber, and
(ii) it shall promptly notify the Company and the Placement Agents if the
Subscriber discovers that any of such representations ceases to be true, and to
provide the Company and the Placement Agents with appropriate information in
connection therewith.

The Subscriber represents and warrants that the current structure of this
transaction and all transactions and activities contemplated hereunder is not a
plan or scheme to evade the registration provisions of the Securities Act.

The Subscriber acknowledges that:

         (i)      no securities commission or similar regulatory authority has
                  reviewed or passed on the merits of the Units or the
                  Underlying Stock; and

         (ii)     there is no government or other insurance covering the Units
                  or Underlying Stock; and

         (iii)    there are risks associated with the purchase of the Units; and

         (iv)     there are restrictions on the Subscriber's ability to resell
                  the Units and the Underlying Stock and it is the
                  responsibility of the Subscriber to find out what those
                  restrictions are and to comply with them before selling the
                  Units and the Underlying Stock; and

                                       6

<PAGE>

         (v)      the Company has advised the Subscriber that the Company is
                  relying on an exemption from the requirements to provide the
                  Subscriber with a prospectus and to sell securities through a
                  person or company registered to sell securities under
                  applicable securities laws and, as a consequence of acquiring
                  the Units pursuant to this exemption, certain protections,
                  rights and remedies provided by applicable securities laws,
                  including statutory rights of rescission or damages, will not
                  be available to the Subscriber.

The Subscriber represents and warrants that it has not received nor does it
expect to receive any financial assistance from the Company, directly or
indirectly, in respect of the Subscriber's purchase of the Units.

The Subscriber represents and warrants that neither the Company nor the
Placement Agents, nor any of their respective directors, officers, employees or
representatives, have made any representations (oral or written) to the
Subscriber regarding the future value of the Units or the Underlying Stock.

The Subscriber acknowledges that (i) the Company may complete secured or
unsecured debt financings or equity financings in the future in order to develop
the Company's business and to fund its ongoing development, (ii) there is no
assurance that such financings will be available and, if available, on
reasonable terms, (iii) any such future financings may have a dilutive effect on
current security holders, including the Subscriber, and (iv) if such future
financings are not available, the Company may be unable to fund its ongoing
development and the lack of capital resources may result in the failure of its
business.

The Subscriber acknowledges that the Placement Agents, their respective
affiliates and their respective directors, officers, employees and companies
with which they are associated may, from time to time, have a long or short
position or deal as principal in the securities of the Company.

C. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

         1. ORGANIZATION, GOOD STANDING AND QUALIFICATION. The Company is a
corporation duly organized, validly existing, in good standing under the laws of
the State of Nevada and has all requisite corporate power and corporate
authority to carry on its business as now conducted and as proposed to be
conducted. The Company is duly qualified to transact business and is in good
standing in the State of Nevada. The Company is duly qualified to transact
business and is in good standing in each jurisdiction in which such
qualification is required, except where the failure to be so qualified would not
have a material adverse effect on the Company.

                                       7

<PAGE>

         2. FINDERS FEES. A finder's fee of up to 7% of the amounts subscribed
for may be paid to anyone acting as a finder in this Offering. Such fee, if any,
shall be payable one-half in cash and one-half in Units.

         3. CAPITALIZATION. As of consummation of the transactions contemplated
hereby and immediately thereafter, the authorized capital stock of the Company
shall consist of 100,000,000 shares of common stock, par value $0.001 per share
(the "Common Stock"), of which (i)__________ shares shall be issued and
outstanding, (ii) shares are reserved for issuance upon exercise of outstanding
warrants, options and other convertible securities, and (iii) _____ shares shall
be reserved for issuance upon the exercise of the Warrants . All such issued and
outstanding shares have been duly authorized and validly issued and have been
offered, issued, sold, and delivered by the Company in compliance with
applicable federal and state securities laws.

         4. AUTHORIZATION. The Company has all requisite corporate power to
execute, deliver and perform its obligations under this Agreement and all other
agreements contemplated hereby and thereby and to issue the Units and the
Underlying Stock in accordance with the terms hereof. All corporate action on
the part of the Company, its officers, directors and shareholders necessary for
the authorization, execution and delivery of this Agreement and all other
agreements and obligations contemplated hereby and thereby, the performance of
all obligations of the Company hereunder and thereunder, and the authorization,
issuance (or reservation for issuance), sale and delivery of the Common Stock to
be issued hereunder has been taken. This Agreement constitutes valid and legally
binding obligations of the Company, enforceable in accordance with their
respective terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally, (ii) as limited by general
principles of equity, including concepts of materiality, reasonableness, good
faith and fair dealing and by the possible unavailability of specific
performance, injunctive relief or other equitable remedies.

         5. NO VIOLATION. The Company's execution, delivery and performance of
this Agreement and all other agreements contemplated hereby and thereby and the
consummation of the transactions contemplated hereby and thereby will not with
or without the giving of notice or the lapse of time or both (A) violate any
provision of law, statute, rule or regulation to which the Company is subject,
(B) violate any order, judgment or decree applicable to it, or (C) conflict with
or result in a breach or default under any term or condition of its applicable
governing instruments or any agreement or other instrument to which it is a
party or by which it is bound.

                                       8

<PAGE>

         6. VALID ISSUANCE OF COMMON STOCK. The Common Stock being issued
hereunder, when issued, sold and delivered in accordance with the terms of this
Agreement for the consideration expressed herein, will be duly and validly
issued, fully paid and nonassessable and will be free of preemptive rights and
restrictions on transfer other than restrictions on transfer under this
Agreement and applicable state and federal securities laws. Assuming the truth
and accuracy of the representations and warranties of each of the Subscribers
for the Company's capital stock under agreements similar to this Agreement, the
issuance of the Units hereunder shall be exempt from registration under the
Securities Act and any applicable state securities laws.

         7. GOVERNMENTAL CONSENTS. No consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company is
required in connection with the valid execution of this Agreement and the
consummation of the transactions contemplated by this Agreement except for
filings pursuant to applicable state and federal securities laws which allow
filings to be made following the Closing but in no event later than 15 days
after the consummation of the transactions contemplated hereby. The Company (a)
is not a Person described or designated in the Specially Designated Nationals
and Blocked Persons List of the Office of Foreign Assets Control or in Section 1
of the Anti-Terrorism Order or (b) does not engage in any dealings or
transactions with any such Person. The Company is in compliance, in all material
respects, with the USA Patriot Act.

         8. USE OF PROCEEDS. The proceeds from the sale of Units will be
available for the Company's general corporate purposes. Up to 7% of the proceeds
may be paid for finders fees which will be paid one-half in cash and one-half in
Units at the Offering Price.

         9. NO SUBSIDIARIES. The Company has four dormant wholly-owned
subsidiaries, Aethlon, Inc, Cell Activation, Inc., Syngen Research, Inc. and
Hemex, Inc.

         10. REGISTRATION RIGHTS

(a) Subject to the terms and limitations hereof, the Company shall file a
registration statement on Form SB-2 or other appropriate registration document
under the Securities Act (the "Registration Statement") for resale of the Common
Stock and Warrant Shares underlying the Warrants (the "Registrable Securities")
and shall use its reasonable best efforts to maintain the Registration Statement
effective so long as any of the Warrants are outstanding (the "Effectiveness
Period"). The Company shall file such Registration Statement no later than sixty
(60) days after the completion of the Offering (the "Closing Date"); provided,
however, the Company will not be obligated to register more than 33% of its
issued and outstanding shares of Common Stock on such registration statement. If
the number of shares of Common Stock and the Warrant Shares exceeds such 33%
limitation, the Company will cut back the number of shares being registered in
order for it to adhere to such 33% limitation, and such cut back will be applied


                                       9

<PAGE>

to the holders of the Units on a pro rata basis. The Company shall also use its
best efforts to ensure that such Registration Statement is declared effective
within one hundred and eighty (180) calendar days from the Closing Date. If the
event the Registration Statement is not declared effective within one hundred
and eighty (180) calendar days from the Closing Date (the "Effective Date"), the
Subscriber will be entitled to receive from the Company, without additional
consideration, additional shares of Common Stock equal to two percent (2%) of
the shares of Common Stock sold in the Offering for each 30-day period (or
portion thereof) after which the Effective Date has passed and the Registration
Statement remains without effectiveness. No "penalty shares" shall accrue or be
issuable if at such time the Registrable Securities may be resold pursuant to
Rule 144 under the Act.

(b) Notwithstanding the foregoing, the Company shall not be obligated to effect
any registration of the Registrable Securities or take any other action pursuant
to this Section 10: (i) in any particular jurisdiction in which the Company
would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is
already subject to service in such jurisdiction and except as may be required by
the Securities Act, or (ii) during any period in which the Company suspends the
rights of a Subscriber after giving the Subscriber written notification of a
Potential Material Event (defined below) pursuant to subsection (i) below.

(c) Except as otherwise expressly set forth, the Company shall bear all expenses
incurred by the Company in compliance with the registration obligation of the
Company, including, without limitation, all registration and filing fees,
printing expenses, fees and disbursements of counsel for the Company incurred in
connection with any registration, qualification or compliance pursuant to this
Subscription Agreement and all underwriting discounts, selling commissions and
expense allowances applicable to the sale of any securities by the Company for
its own account in any registration. All underwriting discounts, selling
commissions and expense allowances applicable to the sale by Subscriber of
Registrable Securities and all fees and disbursements of counsel for the
Subscriber shall be borne by the Subscriber.

(d) To the extent permitted by law the Company will indemnify each Subscriber,
each of its officers, directors, agents, employees and partners, and each person
controlling such Subscriber, with respect to each registration, qualification or
compliance effected pursuant to this Agreement, and each underwriter, if any,
and each person who controls any underwriter, and their respective counsel
against all claims, losses, damages and liabilities (or actions, proceedings or
settlements in respect thereof) arising out of or based on (i) any untrue
statement (or alleged untrue statement) of a material fact contained in any
prospectus, offering circular or other document prepared by the Company
(including any related registration statement, notification or the like)
incident to any such registration, qualification or compliance, or (ii) any
omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, or
any violation by the Company of the Securities Act or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required
of the Company in connection with any such registration, qualification or
compliance, and subject to the provisions of subsection (g) below, will
reimburse each such Subscriber, each of its officers, directors, agents,
employees and partners, and each person controlling such Subscriber, each such


                                       10

<PAGE>

underwriter and each person who controls any such underwriter, for any legal and
any other expenses as they are reasonably incurred in connection with
investigating and defending any such claim, loss, damage, liability or action,
provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability or expense arises out of or is based on
any untrue statement (or alleged untrue statement) or omission (or alleged
omissions) based upon written information furnished to the Company by (or on
behalf of) such Subscriber or underwriter, or if the person asserting any such
loss, claim, damage or liability (or action or proceeding in respect thereof)
did not receive a copy of an amended preliminary prospectus or the final
prospectus (or the final prospectus as amended and supplemented) at or before
the written confirmation of the sale of such Registrable Securities to such
person because of the failure of the Subscriber or underwriter to so provide
such amended preliminary or final prospectus (or the final prospectus as amended
and supplemented); provided, however, that the indemnity agreement contained in
this subsection shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it arises out of or is based upon a
violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
the Subscriber, any such partner, officer, director, employee, agent or
controlling person of such Subscriber, or any such underwriter or any person who
controls any such underwriter; provided, however, that the obligations of the
Company hereunder shall be limited to an amount equal to the portion of net
proceeds represented by the Registrable Securities pursuant to this Agreement.

(e) To the extent permitted by law, each Subscriber whose Registrable Securities
are included in any registration, qualification or compliance effected pursuant
to this Subscription Agreement will indemnify the Company, and its directors,
officers, agents, employees and each underwriter, if any, of the Company's
securities covered by such a registration statement, each person who controls
the Company or such underwriter within the meaning of the Securities Act and the
rules and regulations thereunder, each other such Subscriber and each of their
officers, directors, partners, agents and employees, and each person controlling
such Subscriber, and their respective counsel against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based
on any untrue statement (or alleged untrue statement) of a material fact
contained in any such registration statement, prospectus, offering circular or
other document, or any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, and will reimburse the Company and such Subscribers,
directors, officers, partners, persons, underwriters or control persons for any
legal or any other expenses as they are reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability or action, in
each case to the extent, but only to the extent, that such untrue statement (or
alleged untrue statement) or omission (or alleged omission) is made in such
registration statement, prospectus, offering circular or other document in
reliance upon and in conformity with written information furnished to the
Company by such Subscriber; PROVIDED, HOWEVER, that the obligations of any
Subscriber hereunder shall be limited to an amount equal to the net proceeds to
such Subscriber from Registrable Securities sold under such registration
statement, prospectus, offering circular or other document as contemplated
herein; provided, further, that the indemnity agreement contained in this
subsection shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the
consent of the Subscriber, which consent shall not be unreasonably withheld or
delayed.

                                       11

<PAGE>

(f) Each party entitled to indemnification under this Section (the "Indemnified
Party") shall give notice to the party required to provide indemnification (the
"Indemnifying Party") promptly after such Indemnified Party has actual knowledge
of any claim as to which indemnity may be sought, and shall permit the
Indemnifying Party to assume the defense of any such claim or any litigation
resulting therefrom, provided that counsel for the Indemnifying Party, who shall
conduct the defense of such claim or any litigation resulting therefrom, shall
be approved by the Indemnified Party (whose approval shall not unreasonably be
withheld), and the Indemnified Party may participate in such defense at such
party's expense; and provided further that if any Indemnified Party reasonably
concludes that there may be one or more legal defenses available to it that are
not available to the Indemnifying Party, or that such claim or litigation
involves or could have an effect on matters beyond the scope of this Agreement,
then the Indemnified Party may retain its own counsel at the expense of the
Indemnifying Party; and provided further that the failure of any Indemnified
Party to give notice as provided herein shall not relieve the Indemnifying Party
of its obligations under this Agreement unless and only to the extent that such
failure to give notice results in material prejudice to the Indemnifying Party.
No Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party
of a release from all liability in respect to such claim or litigation. Each
Indemnified Party shall furnish such information regarding itself or the claim
in question as an Indemnifying Party may reasonably request in writing and as
shall be reasonably required in connection with defense of such claim and
litigation resulting therefrom.

(g) If the indemnification provided for in this Section is held by a court of
competent jurisdiction to be unavailable to an Indemnified Party with respect to
any loss, liability, claim, damage or expense referred to herein, then the
Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder,
shall contribute to the amount paid or payable by such Indemnified Party as a
result of such loss, liability, claim, damage or expense in such proportion as
is appropriate to reflect the relative fault of the Indemnifying Party on the
one hand and of the Indemnified Party on the other in connection with the
statements or omissions which resulted in such loss, liability, claim, damage or
expense as well as any other relevant equitable considerations. The relative
fault of the Indemnifying Party and of the Indemnified Party shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to
information supplied by the Indemnifying Party or by the Indemnified Party and
the parties' relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.

(h) The Registrable Securities, and any related benefits to the Subscriber
hereunder may be transferred or assigned by the Subscriber to a permitted
transferee or assignee, provided that the Company is given written notice of
such transfer or assignment, stating the name and address of said transferee or
assignee and identifying the Registrable Securities with respect to which such
registration rights are being transferred or assigned; provided further that the
transferee or assignee of such Registrable Securities shall be deemed to have
assumed the obligations of the Subscriber under this Agreement by the acceptance
of such assignment and shall, upon request from the Company, evidence such
assumption by delivery to the Company of a written agreement assuming such
obligations of the Subscriber.

                                       12

<PAGE>

(i) Subscriber covenants and agrees that such Subscriber will comply with the
prospectus delivery requirements of the Securities Act as applicable to such
Subscriber in connection with sales of Registrable Securities pursuant to the
registration statement required hereunder.

         11. NO STOCK AGREEMENTS. There is not in effect on the date hereof any
agreement to which the Company or (to its knowledge) any holders of equity
securities of the Company is a party relating to the voting, transfer or sale of
such securities.

D. LEGEND. The certificate representing the Underlying Stock and the Warrants
issued by the Company shall bear the following (or similar) legends:

         THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
         UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR
         THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN
         RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE
         SECURITIES ACT AND SUCH LAWS. THESE SECURITIES MAY NOT BE SOLD,
         TRANSFERRED OR ASSIGNED UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION
         STATEMENT OR EXEMPTION THEREFROM.

E. INDEMNIFICATION. The Subscriber agrees to indemnify and hold harmless the
Company and its officers, managers, members, employees, agents and affiliates
against any and all loss, liability, claim, damage and expense whatsoever
(including without limitation any and all expenses reasonably incurred in
investigating, preparing or defending against any litigation commenced or
threatened or any claim whatsoever) arising out of or based upon any false
representation or warranty or breach or failure by the Subscriber to comply with
any covenant agreement made by the Subscriber herein. The Company agrees to
indemnify and hold harmless the Subscriber and its officers, managers, members,
employees, agents and affiliates against any and all loss, liability, claim,
damage and expense whatsoever (including without limitation any and all expenses
reasonably incurred in investigating, preparing or defending against any
litigation commenced or threatened or any claim whatsoever) arising out of or
based upon any false representation or warranty or breach or failure to comply
with any covenant agreement made by the Company herein.

                                       13

<PAGE>

F. MODIFICATION. Neither this Agreement nor any provision hereof shall be
waived, modified, discharged or terminated except by an instrument in writing
signed by the party against whom any such waiver, modification, discharge or
termination is sought.

G. ASSIGNABILITY. This Agreement and the rights and obligations hereunder are
not transferable or assignable by the Subscriber.

H. APPLICABLE LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Nevada, without regard to principles of
conflicts of law.

I. SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All representations and
warranties made by the Subscriber in this Agreement shall survive the execution
and delivery of this Agreement, as well as any investigation at any time made by
or on behalf of the Company and the issue and sale of the Units and Underlying
Stock.

J. RELIANCE. The Subscriber understands and acknowledges that the Subscriber's
representations, warranties, acknowledgements and agreements in this Agreement
will be relied upon by the Company in determining the Subscriber's suitability
as a purchaser of Units.

K. FURTHER ASSURANCES. The Subscriber agrees to provide, if requested, any
additional information that may be requested or required to determine the
Subscriber's eligibility to purchase the Units.

L. ENTIRE AGREEMENT. This Agreement constitutes the full and entire
understanding and agreement between the parties with regard to the subject
matter hereof and no party shall be liable or bound to any other in any manner
by any representations, warranties, covenants and agreements except as
specifically set forth herein and therein.

M. SEVERABILITY. In the event one or more of the provisions of this Agreement
should, for any reason, be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any
other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained
herein.

                                       14

<PAGE>


         IN WITNESS WHEREOF, the undersigned has executed this Agreement as of
the date set forth on this signature page.

         Class and number of Units Subscribed for:   ___________________________

         Aggregate Purchase Price:                   ___________________________

         __________________________________          ___________________________
         Print Name of Individual, Company,          Print Name of Authorized
         Limited                                     Representative
         Liability Company, Corporation
         or Trust

         By:________________________________         ___________________________
         Signature of Authorized Representative      Capacity of Authorized
                                                     Representative
         Date:    _____________
         Address: _______________________


         Social Security Number of Tax Identification No: ______________________

SUBSCRIPTION ACCEPTED:

AETHLON MEDICAL, INC., a Nevada corporation

By:___________________________
      Name:  James A. Joyce                          Date: ____________, 2007
      Title:  CEO


                          Return Executed Document To:

                              Aethlon Medical, Inc.
                       3030 Bunker Hill Street, Suite 4000
                              San Diego, CA. 92109
                               Phone: 858-459-7800
                  Attention: Jim Dorst, Chief Financial Officer


                                       15


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
